Myriad Genetics Inc
NASDAQ:MYGN
Intrinsic Value
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. [ Read More ]
The intrinsic value of one MYGN stock under the Base Case scenario is 20.76 USD. Compared to the current market price of 21.57 USD, Myriad Genetics Inc is Overvalued by 4%.
Valuation Backtest
Myriad Genetics Inc
Run backtest to discover the historical profit from buying and selling MYGN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Myriad Genetics Inc's business.
What risks and challenges
does Myriad Genetics Inc face in the near future?
Summarize the latest earnings report
of Myriad Genetics Inc.
Provide P/E
for Myriad Genetics Inc and its competitors.
Balance Sheet Decomposition
Myriad Genetics Inc
Current Assets | 313.6m |
Cash & Short-Term Investments | 140.9m |
Receivables | 114.3m |
Other Current Assets | 58.4m |
Non-Current Assets | 832.9m |
PP&E | 180.6m |
Intangibles | 636.9m |
Other Non-Current Assets | 15.4m |
Current Liabilities | 155.9m |
Accounts Payable | 25.8m |
Accrued Liabilities | 104.8m |
Other Current Liabilities | 25.3m |
Non-Current Liabilities | 207.4m |
Long-Term Debt | 38.5m |
Other Non-Current Liabilities | 168.9m |
Earnings Waterfall
Myriad Genetics Inc
Revenue
|
753.2m
USD
|
Cost of Revenue
|
-236.2m
USD
|
Gross Profit
|
517m
USD
|
Operating Expenses
|
-653.9m
USD
|
Operating Income
|
-136.9m
USD
|
Other Expenses
|
-126.4m
USD
|
Net Income
|
-263.3m
USD
|
Free Cash Flow Analysis
Myriad Genetics Inc
What is Free Cash Flow?
MYGN Profitability Score
Profitability Due Diligence
Myriad Genetics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Myriad Genetics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
MYGN Solvency Score
Solvency Due Diligence
Myriad Genetics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Myriad Genetics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MYGN Price Targets Summary
Myriad Genetics Inc
According to Wall Street analysts, the average 1-year price target for MYGN is 24.85 USD with a low forecast of 12.12 USD and a high forecast of 32.55 USD.
Ownership
MYGN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
MYGN Price
Myriad Genetics Inc
Average Annual Return | -13.32% |
Standard Deviation of Annual Returns | 37.41% |
Max Drawdown | -79% |
Market Capitalization | 1.9B USD |
Shares Outstanding | 89 874 896 |
Percentage of Shares Shorted | 6.15% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,400 full-time employees. The firm primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing the disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression, and includes corporate services, such as finance, human resources, legal and information technology. The firm discovers and commercializes genetic tests. The firm's products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight and Prequel, GeneSight, Vectra. The Company’s wholly owned subsidiaries include Myriad Genetic Laboratories, Inc., Assurex Health, Inc., Myriad Women’s Health, Inc, Myriad Genetics Espana SL, Myriad Genetics S.r.l., Myriad Genetics B.V. and Myriad Genetics GK.
Contact
IPO
Employees
Officers
The intrinsic value of one MYGN stock under the Base Case scenario is 20.76 USD.
Compared to the current market price of 21.57 USD, Myriad Genetics Inc is Overvalued by 4%.